Thane Jones

Thane Jones

Auto-generated profile, based on publicly available information

Thane Jones

Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in ACS Omega
Verified
Journal Article
Open access
TJThane Jones
Thane Jones
NMNatalia Monakhova
Natalia Monakhova
FGFlorence Guivel-Benhassine
Florence Guivel-Benhassine
ALAlexander Lepioshkin
Alexander Lepioshkin
TBTimothée Bruel
Timothée Bruel
SESean Ekins
Sean Ekins
There have been relatively few small molecules developed with direct activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two existing antimalarial drugs, pyronaridine and quinacrine, display whole cell activity against SARS-CoV-2 in A549 + ACE2 cells (pretreatment, IC50 = 0.23 and 0.19 μM, respectively) with moderate cytotoxicity (CC50 = 11.53 and 9.24 μM, respectively). Moreover, pyronaridine displays in vitro activity against SARS-CoV-2 PLpro (IC50 = 1.8 μM). Given their existing antiviral activity, these compounds are strong candidates for repurposing against COVID-19 and prompt us to study the structure-activity relationship of the 9-aminoacridine scaffold against SARS-CoV-2 using traditional medicinal chemistry to identify promising new analogs. Our studies identified several novel analogs possessing potent in vitro activity in U2-OS ACE2 GFP 1-10 and 1-11 (IC50 < 1.0 μM) as well as moderate cytotoxicity (CC50 > 4.0 μM). Compounds such as 7g, 9c, and 7e were more active, demonstrating selectivity indices SI > 10, and 9c displayed the strongest activity (IC50 ≤ 0.42 μM, CC50 ≥ 4.41 μM, SI > 10) among them, indicating that it has potential as a new lead molecule in this series against COVID-19.

2 August 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
FUFabio Urbina
Fabio Urbina
TJThane Jones
Thane Jones
JHJoshua S. Harris
Joshua S. Harris
SSScott H. Snyder
Scott H. Snyder
TLThomas Lane
Thomas Lane
SESean Ekins
Sean Ekins

1 November 2023 in ACS Omega
Verified
Journal Article
Open access
EKElena Kazakova
Elena Kazakova
TLThomas Lane
Thomas Lane
TJThane Jones
Thane Jones
APAna C. Puhl
Ana C. Puhl
OROlga Riabova
Olga Riabova
SESean Ekins
Sean Ekins
Yellow fever virus (YFV) transmitted by infected mosquitoes causes an acute viral disease for which there are no approved small-molecule therapeutics. Our recently developed machine learning models for YFV inhibitors led to the selection of a new pyrazolesulfonamide derivative RCB16003 with acceptable in vitro activity. We report that the N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine class, which was recently identified as active non-nucleoside reverse transcriptase inhibitors against HIV-1, can also be repositioned as inhibitors of yellow fever virus replication. As compared to other Flaviviridae or Togaviridae family viruses tested, both compounds RCB16003 and RCB16007 demonstrate selectivity for YFV over related viruses, with only RCB16007 showing some inhibition of the West Nile virus (EC50 7.9 μM, CC50 17 μM, SI 2.2). We also describe the absorption, distribution, metabolism, and excretion (ADME) in vitro and pharmacokinetics (PK) for RCB16007 in mice. This compound had previously been shown to not inhibit hERG, and we now describe that it has good metabolic stability in mouse and human liver microsomes, low levels of CYP inhibition, high protein binding, and no indication of efflux in Caco-2 cells. A single-dose oral PK study in mice has a T1/2 of 3.4 h and Cmax of 1190 ng/mL, suggesting good availability and stability. We now propose that the N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine class may be prioritized for in vivo efficacy testing against YFV.

23 August 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TJThane Jones
Thane Jones
John E. TavisJohn E. Tavis
John E. Tavis
QLQilan Li
Qilan Li
OROlga Riabova
Olga Riabova
NMNatalia Monakhova
Natalia Monakhova
SESean Ekins
Sean Ekins

12 December 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
TJThane Jones
Thane Jones
RRRenuka Raman
Renuka Raman
APAna C. Puhl
Ana C. Puhl
TLThomas Lane
Thomas Lane
OROlga Riabova
Olga Riabova
SESean Ekins
Sean Ekins